Two bipartisan bills target patent abuse
Two bipartisan bills target patent abuse
Still Overpatented, Still Overpriced
Merck’s Scheme to Product Hop Keytruda
How Celgene and Bristol Myers Squibb Used Volume Restrictions to Delay Revlimid Competition
How Pharma and Its Consultants Abuse the Patent System
We Need More Drug Patent Data
Investigating the pharmaceutical industry’s drug patenting practices
Five Patent Predictions for 2025
The Year in Patent Reform
Why Current Legislation to Prevent Patent Thickets Are a Good Start — But Not Enough
Learn more about how you can help build a more equitable system for all